Digirad Corporation provides healthcare solutions in the United States and internationally. More Details
Adequate balance sheet and overvalued.
Share Price & News
How has Digirad's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: DRAD's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: DRAD underperformed the US Healthcare industry which returned 16.6% over the past year.
Return vs Market: DRAD underperformed the US Market which returned 12.6% over the past year.
Price Volatility Vs. Market
How volatile is Digirad's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StA Look At Digirad's (NASDAQ:DRAD) CEO Remuneration
3 months ago | Simply Wall StInsider Buying: The Digirad Corporation (NASDAQ:DRAD) Chairman of the Board Just Bought 48% More Shares
3 months ago | Simply Wall StWhat Kind Of Investor Owns Most Of Digirad Corporation (NASDAQ:DRAD)?
Is Digirad undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate DRAD's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate DRAD's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: DRAD is unprofitable, so we can't compare its PE Ratio to the US Healthcare industry average.
PE vs Market: DRAD is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate DRAD's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: DRAD is good value based on its PB Ratio (0.6x) compared to the US Healthcare industry average (2.9x).
How is Digirad forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: DRAD is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: DRAD is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: DRAD is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: DRAD's revenue (18.6% per year) is forecast to grow faster than the US market (9.7% per year).
High Growth Revenue: DRAD's revenue (18.6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if DRAD's Return on Equity is forecast to be high in 3 years time
How has Digirad performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: DRAD is currently unprofitable.
Growing Profit Margin: DRAD is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: DRAD is unprofitable, and losses have increased over the past 5 years at a rate of 47.8% per year.
Accelerating Growth: Unable to compare DRAD's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DRAD is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (31.1%).
Return on Equity
High ROE: DRAD has a negative Return on Equity (-14.4%), as it is currently unprofitable.
How is Digirad's financial position?
Financial Position Analysis
Short Term Liabilities: DRAD's short term assets ($32.9M) exceed its short term liabilities ($24.3M).
Long Term Liabilities: DRAD's short term assets ($32.9M) exceed its long term liabilities ($23.3M).
Debt to Equity History and Analysis
Debt Level: DRAD's debt to equity ratio (61.8%) is considered high.
Reducing Debt: Insufficient data to determine if DRAD's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: DRAD has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: DRAD has sufficient cash runway for 1.8 years if free cash flow continues to reduce at historical rates of 22.1% each year.
What is Digirad current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate DRAD's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate DRAD's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if DRAD's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if DRAD's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: DRAD is not paying a notable dividend for the US market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of DRAD's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Matt Molchan (53 yo)
Mr. Matthew Gabel Molchan, also known as Matt, has been the Chief Executive Officer and Director of Digirad Corporation since July 1, 2013 and has been its President since February 2013. Mr. Molchan served ...
CEO Compensation Analysis
Compensation vs Market: Matt's total compensation ($USD809.76K) is above average for companies of similar size in the US market ($USD589.17K).
Compensation vs Earnings: Matt's compensation has increased whilst the company is unprofitable.
|CFO & COO||1.67yrs||US$695.77k||1.1% |
|President of Digirad Imaging Solutions||4.67yrs||US$492.94k||0.13% |
|Vice President of Legal & Finance||no data||no data||no data|
|Senior Director of Human Resource||no data||no data||no data|
Experienced Management: DRAD's management team is considered experienced (4.7 years average tenure).
|Independent Director||1.67yrs||US$63.38k||1.03% |
|Independent Director||12.5yrs||US$62.07k||0.44% |
|Independent Director||6.67yrs||US$65.07k||0.35% |
|Executive Chairman of Digirad Imaging Solutions||8.67yrs||no data||no data|
|Chairman of the Board||7.58yrs||US$63.91k||2.92% |
Experienced Board: DRAD's board of directors are considered experienced (7.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 129.7%.
Digirad Corporation's company bio, employee growth, exchange listings and data sources
- Name: Digirad Corporation
- Ticker: DRAD
- Exchange: NasdaqGM
- Founded: 1985
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: US$12.591m
- Shares outstanding: 4.70m
- Website: https://www.digirad.com
Number of Employees
- Digirad Corporation
- 1048 Industrial Court
- Suite E
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|DRAD||NasdaqGM (Nasdaq Global Market)||Yes||Common Stock||US||USD||Jun 2004|
|FDV1||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Jun 2004|
|DRAD.P||NasdaqGM (Nasdaq Global Market)||10% CUM SR A PFD||US||USD||Sep 2019|
Digirad Corporation provides healthcare solutions in the United States and internationally. It operates through five segments: Diagnostic Services, Diagnostic Imaging, Mobile Healthcare, Building and Const ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/09/20 06:22|
|End of Day Share Price||2020/09/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.